Posterior Cruciate Retaining (PCR) Versus Posterior Cruciate Substituting (PCS) Total Knee Arthroplasty (TKA) (SCORPIO™)

July 23, 2021 updated by: University of Alberta

SCORPIO™ Posterior Stabilized Versus Posterior Retained Total Knee Arthroplasties: Long-term Functional and Radiographic Outcome

This randomized clinical trial (RCT) examined 10 year outcomes comparing SCORPIO™ Posterior Cruciate Substituting (PCS) versus Posterior Cruciate Retaining (PCR) Total Knee Arthroplasty (TKA) as the primary outcome.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

RCT of 100 subjects undergoing primary TKA who were randomized to received either a SCORPIO™ PCS or PCR TKA.

Subjects were evaluated pre-operatively and at 2 and 10 years post-operatively using the Western Ontario (WOMAC) Osteoarthritis Index, the RAND-36 and knee range of motion (2 years only). Complication and revision rates were also evaluated.

Study Type

Interventional

Enrollment (Actual)

100

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Alberta
      • Edmonton, Alberta, Canada, TG6 2B7
        • Alberta Health Services - Edmonton zone

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • scheduled for primary TKA
  • non-inflammatory arthritis
  • intact Posterior Cruciate Ligament at the time of surgery

Exclusion Criteria:

  • required bone grafting of either the femur or tibia
  • varus or valgus deformity of > 15 degrees
  • previous high tibial osteotomy
  • unable to understand or comply with the study requirements
  • unable to provide signed informed consent

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: PCS
SCORPIO™ Posterior Cruciate Ligament Substituting TKA prosthesis
subjects randomized at surgery to receive 1 of the 2 specified implants
Active Comparator: PCR
SCORPIO™ Posterior Cruciate Ligament Retaining TKA prosthesis
subjects randomized at surgery to receive 1 of the 2 specified implants

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Western Ontario McMaster (WOMAC) Osteoarthritis Index Pain
Time Frame: 10 years postoperative
disease-specific patient reported health related quality of life (pain and function) with 2 constructs (pain; function) each ranging from 0-100 points No total score is calculated; we report the WOMAC in reverse order to align with the RAND-36 scores where higher scores are considered better than lower scores
10 years postoperative
WOMAC Osteoarthritis Index Function
Time Frame: 10 years
disease-specific patient reported health related quality of life (pain and function) with 2 constructs (pain; function) each ranging from 0-100 points No total score is calculated; we report the WOMAC in reverse order to align with the RAND-36 scores where higher scores are considered better than lower scores
10 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
RAND -36 Health Survey
Time Frame: 10 years postoperative
generic patient reported health related quality of life measure with 8 dimensions of health - we report the physical function dimension only with scores ranging from 0-100 where higher scores indicate better physical function.
10 years postoperative
Revision Rate
Time Frame: within 10 years of surgery
number of participants with revision surgery (ie another surgery on the same knee) for any cause data obtained from patient report and regional administrative databases
within 10 years of surgery
Number of Complications
Time Frame: within 10 years of surgery
within 10 years of surgery
Knee Range of Motion
Time Frame: knee ROM at 2 years postoperative
Knee Range of Motion measured as a calculated total of knee flexion + knee extension; measured in degrees
knee ROM at 2 years postoperative

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

February 1, 1999

Primary Completion (Actual)

May 1, 2013

Study Completion (Actual)

May 1, 2013

Study Registration Dates

First Submitted

April 17, 2015

First Submitted That Met QC Criteria

April 28, 2015

First Posted (Estimate)

April 29, 2015

Study Record Updates

Last Update Posted (Actual)

July 27, 2021

Last Update Submitted That Met QC Criteria

July 23, 2021

Last Verified

July 1, 2021

More Information

Terms related to this study

Other Study ID Numbers

  • Pro00002407

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Arthroplasty, Replacement, Knee

Clinical Trials on SCORPIO™

Subscribe